Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors
A. Tuba Kendi, Þorvarður R. Hálfdánarson, Annie T. Packard, et al.
American Journal of Roentgenology (2019) Vol. 213, Iss. 2, pp. 309-317
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements
Brian J. Burkett, David J. Bartlett, Patrick W. McGarrah, et al.
Radiology Imaging Cancer (2023) Vol. 5, Iss. 4
Open Access | Times Cited: 60
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
Damian Wild, Henning Grønbæk, Shaunak Navalkissoor, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 51, Iss. 1, pp. 183-195
Open Access | Times Cited: 20
Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs
Cassandra Miller, Julie Rousseau, Caterina F. Ramogida, et al.
Theranostics (2021) Vol. 12, Iss. 1, pp. 232-259
Open Access | Times Cited: 39
How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy
Brian J. Burkett, Ayca Dundar, Jason R. Young, et al.
Radiology (2020) Vol. 298, Iss. 2, pp. 261-274
Closed Access | Times Cited: 33
A review of advances in the last decade on targeted cancer therapy using 177Lu: focusing on 177Lu produced by the direct neutron activation route.
Rubel Chakravarty, Sudipta Chakraborty
PubMed (2021) Vol. 11, Iss. 6, pp. 443-475
Closed Access | Times Cited: 24
Circlet Sign
Srinivas Ananth Kumar, V. Selvaraj, Madhur Kumar Srivastava
Clinical Nuclear Medicine (2025)
Closed Access
Cumulative radiation doses from recurrent PET–CT examinations
Makoto Hosono, Mamoru Takenaka, Hajime Monzen, et al.
British Journal of Radiology (2021) Vol. 94, Iss. 1126
Open Access | Times Cited: 23
177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
Yasemin Şanlı, Duygu Has Şimşek, Öner Şanlı, et al.
Biomedicines (2021) Vol. 9, Iss. 4, pp. 430-430
Open Access | Times Cited: 21
Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors
Estephany Abou Jokh Casas, Virginia Pubul Núñez, Urbano Anido, et al.
World Journal of Gastroenterology (2020) Vol. 26, Iss. 13, pp. 1513-1524
Open Access | Times Cited: 23
Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Sarit T. Kipnis, Matthew Hung, Shria Kumar, et al.
JAMA Network Open (2021) Vol. 4, Iss. 3, pp. e212274-e212274
Open Access | Times Cited: 19
Renal Neuroendocrine Neoplasms: A Single-center Experience
Patrick W. McGarrah, Gustavo Figueiredo Marcondes Westin, Timothy J. Hobday, et al.
Clinical Genitourinary Cancer (2019) Vol. 18, Iss. 4, pp. e343-e349
Closed Access | Times Cited: 18
Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice
Sara Sheikhbahaei, Mohammad Salehi Sadaghiani, Steven P. Rowe, et al.
American Journal of Roentgenology (2021) Vol. 217, Iss. 2, pp. 495-506
Closed Access | Times Cited: 16
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects
Rahul V. Parghane, Sandip Basu
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 9, pp. 959-975
Closed Access | Times Cited: 6
Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study
Barbara Bober, Marek Saracyn, Kornelia Zaręba, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 4, pp. 919-919
Open Access | Times Cited: 10
Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities
Shagufta Shaheen, Farshad Moradi, Gerardo Gamino, et al.
Current Treatment Options in Oncology (2020) Vol. 21, Iss. 3
Closed Access | Times Cited: 13
Translating a radiolabeled imaging agent to the clinic
Gary L. Griffiths, Crystal Vasquez, Freddy E. Escorcia, et al.
Advanced Drug Delivery Reviews (2021) Vol. 181, pp. 114086-114086
Open Access | Times Cited: 12
Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides—Where Are We Now
Mitesh Naik, Adil Al‐Nahhas, Sairah R. Khan
Cancers (2022) Vol. 14, Iss. 3, pp. 761-761
Open Access | Times Cited: 7
Accuracy of two dosimetry software programs for 177Lu radiopharmaceutical therapy using voxel-based patient-specific phantoms
Keamogetswe Ramonaheng, J.A. van Staden, Hanlie du Raan
Heliyon (2022) Vol. 8, Iss. 7, pp. e09830-e09830
Open Access | Times Cited: 7
Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors
Nandakumar Menon, Mark Mandelkern
Digestive Diseases and Sciences (2022) Vol. 67, Iss. 10, pp. 4633-4653
Open Access | Times Cited: 7
Efficiency and Safety of Targeted Alpha Therapy in Metastatic Neuroendocrine Tumors
Dong Yun Lee, Yong-il Kim
Clinical Nuclear Medicine (2024) Vol. 50, Iss. 1, pp. e1-e6
Closed Access | Times Cited: 1
Carcinoid crisis in Lutetium-177-Dotatate therapy of neuroendocrine tumors: an overview of pathophysiology, risk factors, recognition, and treatment
Stephen J. Sozio, William Raynor, Murray C Becker, et al.
Deleted Journal (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 1
Prospects of nano-theranostic approaches against breast and cervical cancer
Tasnim Ria, Rubi Roy, Uma Sankar Mandal, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189227-189227
Closed Access | Times Cited: 1
Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients
Camila Gadens Zamboni, Ayca Dundar, Sanchay Jain, et al.
Deleted Journal (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 1
Combination of [177Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model
Marina Simón, Jesper Tranekjær Jørgensen, Harshvardhan A. Khare, et al.
Pharmaceutics (2022) Vol. 14, Iss. 6, pp. 1284-1284
Open Access | Times Cited: 6
The Wnt pathway protein Dvl1 targets somatostatin receptor 2 for lysosome-dependent degradation
Heather S. Carr, Yan Zuo, Jeffrey A. Frost
Journal of Biological Chemistry (2023) Vol. 299, Iss. 5, pp. 104645-104645
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top